# BioMarin Pharmaceutical clinical trials: 112 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 112 trials with BioMarin Pharmaceutical as lead sponsor, 10 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by BioMarin Pharmaceutical: 112 rows for $5.60, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/biomarin-pharmaceutical

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 112
- Recruiting or not yet: 10
- Read on: November 19, 2026

## Trials

The 25 newest of 112, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 7, 2026 | NCT07573631 | An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy | BioMarin Pharmaceutical | Phase 2 | Enrolling by invitation | Duchenne Muscular Dystrophy (DMD) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07573631) |
| March 17, 2026 | NCT07477691 | Immune Modulation During Palynziq® Treatment in Adults (IMPALA) | BioMarin Pharmaceutical | Phase 4 | Recruiting | Phenylketonuria | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07477691) |
| March 2, 2026 | NCT07441876 | Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia | BioMarin Pharmaceutical | Phase 2/3 | Recruiting | Achondroplasia | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441876) |
| August 17, 2025 | NCT07126262 | A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to \< 36 Months | BioMarin Pharmaceutical | Phase 2 | Recruiting | Hypochondroplasia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07126262) |
| July 18, 2025 | NCT07073014 | Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia | BioMarin Pharmaceutical | Phase 3 | Enrolling by invitation | Hypochondroplasia | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07073014) |
| January 17, 2025 | NCT06780332 | Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq | BioMarin Pharmaceutical | Phase 4 | Completed | Phenylketonuria, PKU | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06780332) |
| December 17, 2024 | NCT06738017 | Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants | BioMarin Pharmaceutical | Phase 1 | Active not recruiting | Alpha 1-Antitrypsin Deficiency | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06738017) |
| October 31, 2024 | NCT06668805 | A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | BioMarin Pharmaceutical | Phase 2 | Terminated | Noonan Syndrome | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06668805) |
| June 12, 2024 | NCT06455059 | Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia | BioMarin Pharmaceutical | Phase 3 | Completed | Hypochondroplasia | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06455059) |
| April 24, 2024 | NCT06382155 | A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature | BioMarin Pharmaceutical | Phase 2 | Recruiting | Idiopathic Short Stature | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06382155) |
| March 13, 2024 | NCT06309979 | A Study to Assess Growth in Children With Idiopathic Short Stature | BioMarin Pharmaceutical | Observational | Recruiting | Idiopathic Short Stature | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06309979) |
| March 12, 2024 | NCT06305234 | A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade) | BioMarin Pharmaceutical | Observational | Recruiting | Phenylketonuria (PKU) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06305234) |
| February 28, 2024 | NCT06280209 | A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne... | BioMarin Pharmaceutical | Phase 1/2 | Active not recruiting | Duchenne Muscular Dystrophy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06280209) |
| January 25, 2024 | NCT06224907 | Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A | BioMarin Pharmaceutical | Phase 3 | Active not recruiting | Hemophilia A | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06224907) |
| January 19, 2024 | NCT06212947 | A Multicenter Multinational Observational Study of Children With Hypochondroplasia | BioMarin Pharmaceutical | Observational | Recruiting | Hypochondroplasia | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06212947) |
| December 13, 2023 | NCT06168201 | VIrtual STudy in Achondroplasia for the US (VISTA) | BioMarin Pharmaceutical | Observational | Recruiting | Achondroplasia | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06168201) |
| November 18, 2023 | NCT06138327 | A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria | BioMarin Pharmaceutical | Phase 1 | Withdrawn | Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06138327) |
| April 14, 2023 | NCT05813678 | A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace) | BioMarin Pharmaceutical | Observational | Recruiting | Phenylketonuria (PKU) | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05813678) |
| April 14, 2023 | NCT05813314 | Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants | BioMarin Pharmaceutical | Phase 1 | Terminated | Achondroplasia | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05813314) |
| March 14, 2023 | NCT05768386 | A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401) | BioMarin Pharmaceutical | Observational | Enrolling by invitation | Hemophilia A | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05768386) |
| October 14, 2022 | NCT05580692 | A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV) | BioMarin Pharmaceutical | Not applicable | Terminated | Hemophilia A | 321 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05580692) |
| October 14, 2022 | NCT05579548 | A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and... | BioMarin Pharmaceutical | Observational | Recruiting | Phenylketonuria, Maternal | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05579548) |
| March 8, 2022 | NCT05270837 | Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria | BioMarin Pharmaceutical | Phase 3 | Active not recruiting | Phenylketonuria (PKU) | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05270837) |
| November 16, 2021 | NCT05121376 | A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema | BioMarin Pharmaceutical | Phase 1/2 | Active not recruiting | Hereditary Angioedema, HAE | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05121376) |
| December 28, 2020 | NCT04684940 | Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors | BioMarin Pharmaceutical | Phase 1/2 | Completed | Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04684940) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 7 |
| Phase 1/2 | 14 |
| Phase 2 | 29 |
| Phase 2/3 | 1 |
| Phase 3 | 26 |
| Phase 4 | 4 |
| Not applicable | 5 |
| Observational | 26 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 62 |
| Terminated | 20 |
| Active not recruiting | 11 |
| Recruiting | 10 |
| Approved for marketing | 3 |
| Enrolling by invitation | 3 |
| Unknown | 1 |
| No longer available | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Phenylketonurias | 35 |
| Achondroplasia | 14 |
| Genetic Diseases, Inborn | 13 |
| Mucopolysaccharidosis IV | 11 |
| Hemophilia A | 10 |
| Muscular Dystrophy, Duchenne | 10 |
| Dwarfism | 10 |
| Bone Diseases | 10 |
| Lysosomal Storage Diseases | 9 |
| Hemostatic Disorders | 8 |
| Hematologic Diseases | 8 |
| Blood Coagulation Disorders | 8 |
| Blood Coagulation Disorders, Inherited | 8 |
| Coagulation Protein Disorders | 8 |
| Hemorrhagic Disorders | 8 |
| Musculoskeletal Diseases | 8 |
| Mucopolysaccharidosis VI | 7 |
| Bone Diseases, Developmental | 6 |
| Osteochondrodysplasias | 5 |
| Hypochondroplasia | 4 |
| Neuronal Ceroid-Lipofuscinoses | 4 |
| Muscular Dystrophies | 3 |
| Hypertension | 2 |
| Glycogen Storage Disease Type II | 2 |
| Muscular Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Private investigators in the United States](https://specstream.ai/data/businesses/private-investigators/united-states)
- [Maternity centers in the United States](https://specstream.ai/data/businesses/maternity-centers/united-states)
- [Graphic design firms in the United States](https://specstream.ai/data/businesses/graphic-design-firms/united-states)
- [Dermatology practices in the United States](https://specstream.ai/data/businesses/dermatology-practices/united-states)
- [Bathroom remodelers in the United States](https://specstream.ai/data/businesses/bathroom-remodelers/united-states)
